Charles Schwab
ASMB icon

Charles Schwab’s Assembly Biosciences ASMB Stock Holding History

Charles Schwab’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,704
Closed -$228K – 3460
2025
Q4 		$228K Buy
+6,704
New +$216K ﹤0.01% 3329
2024
Q1 		– Sell
-2,704
Closed -$26.6K – 3473
2023
Q4 		$26.6K Hold
2,704
– – ﹤0.01% 3462
2023
Q3 		$28.7K Hold
2,704
– – ﹤0.01% 3474
2023
Q2 		$37.3K Hold
2,704
– – ﹤0.01% 3463
2023
Q1 		$27.3K Hold
2,704
– – ﹤0.01% 3463
2022
Q4 		$42.2K Hold
2,704
– – ﹤0.01% 3393
2022
Q3 		$54K Hold
2,704
– – ﹤0.01% 3314
2022
Q2 		$69K Sell
2,704
-1,577
-37% -$36.3K ﹤0.01% 3336
2022
Q1 		$106K Buy
+4,281
New +$91.9K ﹤0.01% 3403
2021
Q3 		– Sell
-16,171
Closed -$753K – 3504
2021
Q2 		$753K Sell
16,171
-2,389
-13% -$118K ﹤0.01% 3027
2021
Q1 		$1.02M Buy
18,560
+675
+4% +$44.7K ﹤0.01% 2850
2020
Q4 		$1.3M Sell
17,885
-1,638
-8% -$192K ﹤0.01% 2701
2020
Q3 		$3.85M Buy
19,523
+1,933
+11% +$487K ﹤0.01% 2207
2020
Q2 		$4.92M Buy
17,590
+2,301
+15% +$537K ﹤0.01% 2039
2020
Q1 		$2.72M Buy
15,289
+2,440
+19% +$523K ﹤0.01% 2140
2019
Q4 		$3.15M Buy
12,849
+2,434
+23% +$448K ﹤0.01% 2254
2019
Q3 		$1.23M Buy
10,415
+6
+0.1% +$908 ﹤0.01% 2513
2019
Q2 		$1.69M Buy
10,409
+529
+5% +$101K ﹤0.01% 2426
2019
Q1 		$2.33M Buy
9,880
+195
+2% +$49.4K ﹤0.01% 2311
2018
Q4 		$2.63M Buy
9,685
+124
+1% +$35.9K ﹤0.01% 2219
2018
Q3 		$4.26M Buy
9,561
+6,530
+215% +$3.06M ﹤0.01% 2136
2018
Q2 		$1.43M Buy
3,031
+98
+3% +$51.8K ﹤0.01% 2477
2018
Q1 		$1.73M Buy
2,933
+316
+12% +$196K ﹤0.01% 2372
2017
Q4 		$1.42M Buy
2,617
+667
+34% +$302K ﹤0.01% 2421
2017
Q3 		$818K Hold
1,950
– – ﹤0.01% 2562
2017
Q2 		$484K Buy
+1,950
New +$549K ﹤0.01% 2703
2016
Q2 		– Sell
-1,722
Closed -$104K – 3110
2016
Q1 		$104K Hold
1,722
– – ﹤0.01% 2987
2015
Q4 		$156K Hold
1,722
– – ﹤0.01% 3005
2015
Q3 		$198K Hold
1,722
– – ﹤0.01% 2960
2015
Q2 		$399K Buy
+1,722
New +$332K ﹤0.01% 2762

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Charles Schwab's ASMB Position: Q1 2026 in Review

Charles Schwab sold out of Assembly Biosciences (ASMB) in Q1 2026, closing a stake of 6,704 shares — an estimated $228K sold.

Charles Schwab first reported a position in ASMB in Q2 2015 and held it in 30 quarters. The position peaked at $4.92M in Q2 2020. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Charles Schwab reported no remaining Assembly Biosciences position as of Q1 2026 after selling out during the quarter.
  • Charles Schwab sold 6,704 Assembly Biosciences shares in Q1 2026, an estimated $228K.
  • Charles Schwab first reported a position in Assembly Biosciences in Q2 2015 and held it in 30 quarters.
  • Charles Schwab's Assembly Biosciences position peaked at $4.92M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.